Q&A: No­vo Nordisk dig­i­tal in­no­va­tion chief Amy West dis­cuss­es phar­ma pain points and a health­care 'easy but­ton’

Yesterday
Pharma
Marketing

Sanofi turns to a Jen­nifer Doud­na gene edit­ing up­start for next-gen NK cell al­liance

Last week
Deals

Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

Last week
R&D
Pharma

The End­points 11: Fire­side chat with No­bel Prize lau­re­ate Phil Sharp

Last week

An­ti­bod­ies once act­ed on­ly as pro­tein block­ers. Now, sci­en­tists are find­ing new ways to make them pro­tein de­stroy­ers

Last week
Discovery

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Last week
Special

Lab coats and mi­cro­scopes in mar­ket­ing: Does sci­ence still sell in phar­ma ad­ver­tis­ing?

3 weeks ago
Pharma
Marketing

#ES­MO22: Round­table dis­cus­sion with John Car­roll

3 weeks ago

Backed by five phar­ma gi­ants and a crew of Penn su­per­stars, a start­up us­es mR­NA to cre­ate in vi­vo CAR-T — with a pro at the helm

3 weeks ago
Financing
Startups

#ES­MO22: Am­gen drops the de­tailed deck for KRAS G12C, with erod­ing da­ta like­ly to trig­ger fresh de­bate

4 weeks ago
R&D

#ES­MO22: 'End of the be­gin­ning': As PD-(L)1s press on, how far can com­bo ther­a­pies take im­muno-on­col­o­gy?

4 weeks ago
R&D
Pharma

#ES­MO22: Am­gen spot­lights con­fir­ma­to­ry win for KRAS G12C play­er Lumakras in lung can­cer — but there's plen­ty more da­ta to come

4 weeks ago
R&D

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

5 weeks ago
Pharma
Marketing

Phar­ma's day in court: Is the dai­ly down­pour of law­suits giv­ing phar­ma com­pa­nies a bad rep?

Last month
Pharma
Marketing

Chi­na's DNA gi­ant con­fronts skep­ti­cism in US ex­pan­sion bid

Last month
China
In Focus

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

Last month
R&D
In Focus

Q&A: GSK vac­cine leader Judy Stew­art nav­i­gates vac­ci­na­tion slumps, al­ways-on mar­ket­ing and in­no­vat­ing da­ta tools

Last month
Pharma
Marketing

Biotech's 'sug­ar high' led to a cor­rec­tion, but win­ter dol­drums could make way for a turn­around sto­ry this fall

Last month
Financing
In Focus

Biotech’s down­turn fu­els a bil­lion­aire’s niche in­vest­ment in­dus­try

Last month
R&D
In Focus

ICY­MI: James Sabry just signed off on a land­mark first for Roche's deal­mak­ing crew

Last month
Bioregnum
China

Those big bil­lion-dol­lar PhI­II stud­ies? Mar­tin Lan­dray says they can be done for a tiny frac­tion of the cost

Last month
R&D
In Focus

Cerev­el's Tony Coles is still count­ing his mon­ey as a ri­val's boost helps fu­el a po­ten­tial $609M wind­fall

Last month
Financing
Bioregnum

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

Last month
Cell/Gene Tx

'Messy at best': Is the US re­peat­ing the same Covid mis­steps with mon­key­pox mes­sag­ing?

Last month
Pharma
Marketing
1234 Next page Last page